{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-21-000048","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2021-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.082130+00:00","generated_at":"2026-06-29T23:59:36.141965+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Keros Therapeutics appoints Simon Cooper as CMO effective Aug 2; Ordonez departs","bullets":["Simon Cooper appointed CMO effective Aug 2, 2021; succeeds Claudia Ordonez who departed July 30.","Dr. Cooper previously SVP/CMO at Kadmon; prior roles at Anokion, AbbVie, Sanofi, Novartis.","Ordonez gets 9-month base salary severance, acceleration on 7,603 options, COBRA up to 9 months, $5k consulting fee.","Cooper receives $450k base salary, 40% target bonus, option for 60,000 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-21-000048","json":"https://secwatch.observer/filing/0001664710-21-000048.json","markdown":"https://secwatch.observer/filing/0001664710-21-000048.md","text":"https://secwatch.observer/filing/0001664710-21-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471021000048/0001664710-21-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471021000048/keros-form8xk.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T23:59:36.141965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1638ab147f","claim":"Simon Cooper was appointed as Chief Medical Officer at Keros Therapeutics, Inc..","evidence_excerpt":"Simon Cooper, M.B.B.S., has been appointed to serve as the Company’s Chief Medical Officer, effective as of August 2, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471021000048/0001664710-21-000048-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"c43dcb6bba","claim":"Claudia Ordonez departed as Chief Medical Officer at Keros Therapeutics, Inc..","evidence_excerpt":"Dr. Cooper is succeeding Claudia Ordonez, M.D., who departed from the Chief Medical Officer position effective July 30, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471021000048/0001664710-21-000048-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}